NCT04324528View on ClinicalTrials.gov

Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

January 27, 2021

Study Completion Date

January 27, 2021

Conditions
CoronavirusCOVID-19SARS-CoV InfectionRespiratory FailureCytokine Storm
Interventions
DEVICE

vv-ECMO + cytokine adsorption (Cytosorb adsorber)

in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)

DEVICE

vv-ECMO only (no cytokine adsorption)

COVID-19-diseased treated with vv-ECMO

Trial Locations (1)

79108

University Clinic Freiburg, Freiburg im Breisgau

All Listed Sponsors
lead

Dr. Alexander Supady

OTHER

NCT04324528 - Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation | Biotech Hunter | Biotech Hunter